Human research into creatine and choline for dementia-related memory loss is far too sparse to justify either as a proven treatment. Creatine in Alzheimer's disease has only recently entered human testing—the first clinical trial was published in May 2025—while choline research consists almost entirely of observational studies on food intake, not controlled trials of supplements in dementia patients.
Most claims about either compound rest on animal models or mechanisms, not evidence that actually works in people with cognitive decline. The gap between what animal studies suggest and what humans need matters. This article explains what that first creatine trial found, why it cannot yet answer whether creatine helps, where choline evidence stands, and what the evidence does and does not support for real decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- The First Creatine Trial in Alzheimer's Patients—and Its Limits
- Broader Evidence Does Not Show Creatine Improves General Cognition
- Choline Research Relies on Dietary Intake, Not Supplement Trials
- Animal Studies Show Promise—Human Translation Remains Unknown
- What You Can Do Given the Gaps in Evidence
- Why These Gaps Matter for Care Decisions
- Frequently Asked Questions
The First Creatine Trial in Alzheimer's Patients—and Its Limits
The CABA trial enrolled only 19 Alzheimer's patients ages 60–90 in an 8-week pilot, each receiving 20 grams of creatine monohydrate powder daily. The study found an 11% increase in brain total creatine and modest improvements on working memory and executive function tests. For a first human test in a new disease area, this is a necessary starting step—but it is not proof the treatment works.
A pilot with no control group cannot distinguish between true drug effect and placebo effect, natural variation in cognition, or chance. Because researchers measured only 19 people and gave all of them the same dose, they have no comparison group to tell whether the memory improvements happened because of creatine or would have happened anyway. This is why even the researchers designed it as a feasibility study, not an efficacy test.
Broader Evidence Does Not Show Creatine Improves General Cognition
A 2025 meta-analysis of creatine supplementation across the general population found no significant improvements on overall cognitive function or executive function. Subgroup analysis suggested potential benefit in people already diagnosed with disease and in women, but the overall signal remains mixed and preliminary. One small Alzheimer's pilot with encouraging preliminary data does not overturn a broader review that found limited effect.
This matters because the CABA trial's cognitive gains may be real—or they may reflect the 11% rise in measurable brain creatine without translating to lasting clinical benefit. We do not yet know. Larger controlled trials would need to test both creatine and a placebo in comparable groups to tell whether memory improvements are genuine.
Choline Research Relies on Dietary Intake, Not Supplement Trials
Choline research for dementia follows a different path. A UK Biobank study of over 100,000 participants found a U-shaped relationship: moderate dietary choline intake showed lower dementia risk than very low intake, but very high intake showed no additional benefit. This observational finding is useful—it suggests choline is relevant to brain health—but it does not test whether choline *supplements* prevent or slow dementia.
Randomized controlled trials of choline supplementation specifically in dementia patients are largely absent. Most human choline evidence comes from food intake surveys linked to later dementia rates, a weaker type of evidence than a trial where researchers give some people a supplement and others a placebo, then follow both groups. A dietary association does not prove that taking a pill will help.
Animal Studies Show Promise—Human Translation Remains Unknown
Lifelong choline supplementation in transgenic mice reduced amyloid-β plaques and improved spatial memory, a pattern researchers hope could carry over to people. Amyloid-β accumulation is a hallmark of Alzheimer's disease, so reducing it in animal brains is scientifically interesting. But animal models often work in ways humans do not.
A drug that clears plaques in mice might fail in people due to blood-brain barrier differences, dose metabolism, or other factors specific to human disease. No long-term human trial of choline supplementation in dementia patients exists to confirm that the mechanism translates. This means if you read marketing material claiming choline supplements "reduce Alzheimer's plaques" or "improve memory," the claim rests on mouse data, not human evidence.
What You Can Do Given the Gaps in Evidence
Neither creatine nor choline supplements have been proven effective for dementia prevention or treatment in humans. If you are considering either:.
- Consult your doctor before starting any supplement, especially if you take medications or have kidney disease (creatine supplements affect kidney function in some people).
- If you choose to try either supplement, monitor for changes in cognition, mood, or physical symptoms and report them to your healthcare provider.
- Moderate dietary choline from eggs, chicken, fish, and vegetables has observational support and poses no supplement risk—emphasis on "moderate," since very high intake showed no additional dementia benefit in the UK study.
- Do not delay or replace proven dementia treatments, cognitive therapy, or lifestyle changes (exercise, cognitive engagement, sleep) while waiting for supplement evidence to mature.
Why These Gaps Matter for Care Decisions
Dementia caregivers and families face enormous pressure to "do something" when diagnosis arrives. Companies marketing creatine or choline supplements capitalize on that urgency and on the fact that neither supplement has been tested rigorously enough to be ruled out.
Absence of proof is not proof of harm, but it is also not proof of benefit. Until larger controlled trials exist, neither supplement has an evidence base that justifies expense or false hope over proven interventions.
Frequently Asked Questions
Should I give my parent with Alzheimer's creatine or choline?
Not yet. A single small pilot study and observational dietary data are not sufficient evidence to recommend either supplement as a treatment. Discuss any supplement you are considering with the doctor managing dementia care.
Is it safe to take creatine or choline supplements?
Creatine is generally considered safe for people with normal kidney function, but creatine supplements increase kidney workload—check with your doctor if you have kidney disease. Choline from food is safe; supplemental choline has less safety data. Both carry risk if they delay use of proven treatments.
What should I focus on instead?
Physical activity, cognitive engagement (reading, puzzles, social interaction), quality sleep, and management of blood pressure and cardiovascular health have evidence supporting cognitive benefit in aging and dementia. Ask your doctor about these and any medications approved for early Alzheimer's disease.
